A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

Summary

The primary objective of this early Phase 1/2 study is to identify the V591 dose that achieves the target immune response in humans based on preclinical or early clinical data.

Timeline

Start

2020-08-27

Primary completion

2021-03-05

Completion

2021-03-05

Outcome

Outcome not reported

Stopped: “The study was terminated based on an interim assessment of immunogenicity”

Publications

• Vanhoutte F, Liu W, Wiedmann RT, Haspeslagh L, Cao X, Boundy K, Aliprantis A, Davila M, Hartzel J, Li J, McGuire M, Ramsauer K, Tomberger Y, Tschismarov R, Brown DD, Xu W, Sachs JR, Russell K, Stoch SA, Lai E. Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial. EBioMedicine. 2022 Jan;75:103811. doi: 10.1016/j.ebiom.2021.103811. Epub 2022 Jan 15.

Drugs

Indications